Key Points
- Annexon director Muneer Satter bought 613,497 shares on May 28 at an average price of $5.41 each, totaling about $3.32 million. After the purchase, he owned 10.34 million shares, a 6.31% increase in his position.
- ANNX shares were trading around $5.42 following the disclosure, giving the company a market cap of about $888 million. The stock has traded between $1.85 and $7.18 over the past 52 weeks.
- Analysts are mixed on Annexon: the consensus rating is currently “Hold,” with an average price target of $16.00. Recent commentary includes a neutral call from Goldman Sachs, while Chardan Capital reiterated a buy rating with a $16 target.
Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director Muneer Satter bought 613,497 shares of the stock in a transaction on Thursday, May 28th. The stock was acquired at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the acquisition, the director owned 10,342,134 shares of the company's stock, valued at $55,950,944.94. This represents a 6.31% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Annexon Stock Performance
Shares of ANNX stock opened at $5.42 on Friday. The company has a market cap of $888.03 million, a P/E ratio of -4.44 and a beta of 1.22. The stock has a 50 day simple moving average of $5.63 and a two-hundred day simple moving average of $5.32. Annexon, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $7.18.
Annexon (NASDAQ:ANNX - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.07. On average, research analysts predict that Annexon, Inc. will post -0.92 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts recently commented on ANNX shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Annexon in a research report on Monday, April 20th. Wall Street Zen raised Annexon from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. The Goldman Sachs Group started coverage on Annexon in a research report on Tuesday, May 12th. They issued a "neutral" rating and a $7.00 target price for the company. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $16.00 target price on shares of Annexon in a research report on Friday, March 20th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $16.00.
Read Our Latest Stock Report on ANNX
Institutional Trading of Annexon
Several institutional investors have recently made changes to their positions in ANNX. AQR Capital Management LLC grew its stake in shares of Annexon by 122.6% in the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company's stock worth $142,000 after acquiring an additional 40,637 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of Annexon by 8.2% in the first quarter. Jane Street Group LLC now owns 99,924 shares of the company's stock valued at $193,000 after acquiring an additional 7,553 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Annexon by 31.1% in the first quarter. Acadian Asset Management LLC now owns 203,990 shares of the company's stock valued at $393,000 after acquiring an additional 48,345 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Annexon by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company's stock valued at $5,484,000 after acquiring an additional 39,763 shares in the last quarter. Finally, American Century Companies Inc. grew its holdings in shares of Annexon by 6.6% in the second quarter. American Century Companies Inc. now owns 211,195 shares of the company's stock valued at $507,000 after acquiring an additional 13,001 shares in the last quarter.
Annexon Company Profile
(
Get Free Report)
Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.
At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
